Newsfeeds - Spark Newswire

1 minute read

Orchard Therapeutics Announced Long-term Results From An Updated Integrated Analysis Of 39 Patients With Metachromatic Leukodystrophy Treated With Investigational OTL-200 In The Clinical Development Program

February 24, 8:09 AM

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite primary endpoint used

ORTX

1 minute read

Uncategorized

Orchard Therapeutics Announces Proposed ADS Ratio Change from One ADS to Ten Ordinary Shares

By Benzinga Newsdesk

February 10, 8:06 AM

The Company anticipates that the ADS Ratio Change will be effective on or about March 10, 2023. For the company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS

ORTX

3 minute read

Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

January 6, 9:00 AM

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.

ABVC

16 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

December 28, 12:23 PM

On Wednesday, 258 companies hit new 52-week lows.

ACB

19 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

December 27, 12:31 PM

Tuesday's session saw 325 companies set new 52-week lows.

AAPL

18 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

December 22, 2:13 PM

Thursday's session saw 329 companies set new 52-week lows.

ABNB

1 minute read

Orchard Therapeutics Announced Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

By Charles Gross

December 1, 8:10 AM

Orchard Therapeutics (NASDAQ: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (atidarsagene autotemcel) has been accepted for evaluation by the Swiss Agency for Therapeutic Products (Swissmedic) for the potential treatment of eligible patients with early-on

ORTX

17 minute read

Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights

November 14, 6:06 AM

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

1 minute read

Orchard Therapeutics Q2 EPS $(0.04) Up From $(0.29) YoY

By Benzinga Newsdesk

August 4, 9:26 AM

Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.04) per share. This is a 86.21 percent increase over losses of $(0.29) per share from the same period last year.

ORTX

3 minute read

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket

By Lisa Levin

August 1, 6:43 AM

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

AEMD